Cargando…
Examining the association between oncology drug clinical benefit and the time to public reimbursement
BACKGROUND: We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO‐MCBS), received public reimbursement status faster t...
Autores principales: | Thomson, Sasha, Everest, Louis, Witzke, Noah, Jiao, Tina, Delos Santos, Seanthel, Nguyen, Vivian, Cheung, Matthew C., Chan, Kelvin K. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729052/ https://www.ncbi.nlm.nih.gov/pubmed/34850587 http://dx.doi.org/10.1002/cam4.4455 |
Ejemplares similares
-
Assessment of Food and Drug Administration– and European Medicines Agency–Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
por: Arciero, Vanessa, et al.
Publicado: (2021) -
Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016) -
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
por: Jiang, Di Maria, et al.
Publicado: (2019) -
Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits
por: Parmar, Ambica, et al.
Publicado: (2019) -
Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)